Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

ClinicalTrials.gov ID: NCT00394173

Public ClinicalTrials.gov record NCT00394173. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of DNK333 25mg b.i.d. Given Orally for 4 Weeks in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Study identification

NCT ID
NCT00394173
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis
Industry
Enrollment
180 participants

Conditions and interventions

Interventions

  • DNK333 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
Female
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2006
Primary completion
Sep 30, 2007
Completion
Sep 30, 2007
Last update posted
Feb 26, 2017

2006 – 2007

United States locations

U.S. sites
37
U.S. states
19
U.S. cities
37
Facility City State ZIP Site status
Investigative Site Tucson Arizona 85712
Investigative Site North Little Rock Arkansas 72114
Investigative Site Los Angeles California 90045-3119
Investigative Site Orange California 92869
Investigative Site Riverside California 92506
Investigative Site Sacramento California 95825
Investigative Site San Diego California 92108
Investigative Site Colorado Springs Colorado 80904
Investigative Site Bristol Connecticut 06010
Investigative Site Hartford Connecticut 06010
Investigative Site Boca Raton Florida 33486
Investigative Site Gainesville Florida 32256
Investigative Site Hollywood Florida 33021
Investigative Site Jacksonville Florida 782091744
Investigative Site Miami Florida 33173
Investigative Site New Smyrna Beach Florida 32168-7327
Investigative Site Tampa Florida 33607
Investigative Site Arlington Heights Illinois 60005
Investigative Site Rockford Illinois 61107
Investigative Site Boston Massachusetts 02215
Investigative Site Wellesley Hills Massachusetts 02481-2106
Investigative Site Mexico Missouri 65265-3726
Investigative Site Buffalo New York 14215
Investigative Site Great Neck New York 11023-2432
Investigative Site Elkin North Carolina 28621
Investigative Site Cincinnati Ohio 45219
Investigative Site Oklahoma City Oklahoma 73104
Investigative Site Portland Oregon 97220
Investigative Site Chattanooga Tennessee 37404
Investigative Site Lake Jackson Texas 77566
Investigative Site San Antonio Texas 78209-1744
Investigative Site Salt Lake City Utah 84102
Investigative Site Chesapeake Virginia 23320-1706
Investigative Site Bellevue Washington 98004
Investigative Site Everett Washington 98208
Investigative Site Monroe Washington 98208
Investigative Site Seattle Washington 98101

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00394173, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 26, 2017 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00394173 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →